Obesity Drugs, Ranked by Real Weight-Loss Data
A BMJ systematic review pooled 262 randomized trials (99,791 participants) to rank 19 obesity drugs by one-year weight change — not marketing claims. Tirzepatide and CagriSema lead; bigger loss generally comes with bigger side effects.
How It Works
A frequentist + Bayesian network meta-analysis of 262 RCTs (≥12 weeks, 99,791 participants) comparing 19 drugs against lifestyle modification, placebo, or each other. Weight change is the reported mean difference at one year versus lifestyle change alone, graded with GRADE certainty.
The paper’s core finding: larger weight loss generally travels with more adverse-event discontinuation and more gastrointestinal and fatigue events. The "best" number on the chart is rarely the best-tolerated drug.
Tirzepatide, CagriSema, oral and subcutaneous semaglutide sit on moderate-to-high certainty evidence. Emerging agents — retatrutide, mazdutide, ecnoglutide — show 13–15% but on very-low to low certainty (small early trials), so their rank could move.
Only subcutaneous semaglutide showed reduced all-cause mortality and heart attack (largely from high-risk cardiovascular trials). No drug convincingly improved quality of life beyond the minimally important threshold across 43 trials.
What the Data Shows
Key Takeaways
- Across 262 trials and 99,791 people, tirzepatide (−14.9%) and CagriSema (−14.8%) produced the largest one-year weight loss versus lifestyle modification, on moderate-to-high certainty evidence.
- Oral semaglutide (−10.9%), orforglipron (−9.9%), subcutaneous semaglutide (−9.8%) and phentermine–topiramate (−8.1%) form the next tier.
- Emerging triple/dual agonists — retatrutide, mazdutide, ecnoglutide — posted 13–15% but only on very-low to low certainty, so they are promising, not proven.
- Larger weight loss generally came with more adverse-event discontinuation (risk ratios 1.9–4.2) and more GI events (naltrexone–bupropion, oral semaglutide, orforglipron, tirzepatide highest).
- Only subcutaneous semaglutide showed reduced all-cause mortality (RR 0.81) and myocardial infarction (RR 0.72), driven by high-risk cardiovascular outcome trials.
- Tirzepatide cut fat mass the most (−25.7%) but also cut lean mass the most (−8.3%) — a reason resistance training and protein matter on any of these drugs.
- Whether the emerging agents (retatrutide, mazdutide, ecnoglutide) truly beat tirzepatide — their evidence is early, small, and low-certainty; head-to-head trials are still needed.
- That any of these drugs meaningfully improve quality of life — no drug crossed the minimally important difference across 43 trials with 45,663 participants.
- How weight loss and side effects compare with research-grade or compounded product versus the studied branded doses.
- Long-term (multi-year) durability and what happens on discontinuation for most agents — most trials ran 1–2 years.
- This ranking is population-average; individual response, tolerability, cost and access can reorder the list for any one person. It is not personalized medical advice.
Frequently Asked Questions
What is the most effective weight-loss drug in 2026?
In the 2026 BMJ network meta-analysis of 262 trials, tirzepatide produced the largest one-year weight loss (mean difference −14.9% versus lifestyle modification), essentially tied with CagriSema (−14.8%). Both rest on moderate-to-high certainty evidence, but the largest weight loss also tends to bring more side effects.
How does tirzepatide compare to semaglutide for weight loss?
In the same analysis, tirzepatide (−14.9% at one year) produced more weight loss than subcutaneous semaglutide (−9.8%) or oral semaglutide (−10.9%). However, subcutaneous semaglutide was the only drug that also showed reduced all-cause mortality and heart attack risk, largely from cardiovascular outcome trials.
Are retatrutide and CagriSema better than tirzepatide?
CagriSema matched tirzepatide (−14.8% vs −14.9%) on solid evidence. Retatrutide, mazdutide and ecnoglutide posted 13–15% but only on very-low to low certainty from small early trials, so they may match or exceed tirzepatide — the evidence is not yet strong enough to confirm it.
Do obesity drugs improve quality of life?
According to the BMJ analysis, no. Across 43 trials with 45,663 participants, no drug improved quality-of-life scores beyond the established minimally important difference — all mean differences were under 5 points against a threshold of 10.
Which weight-loss drug has the fewest side effects?
The analysis did not crown a single "cleanest" drug, but discontinuation from adverse events was highest with orforglipron, naltrexone–bupropion, liraglutide, phentermine–topiramate, CagriSema and oral semaglutide (risk ratios 1.9–4.2). Tolerability is individual, and larger weight loss generally tracked with more GI and fatigue events.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
Weight-loss medications are prescription drugs; decisions about them belong with a licensed clinician. Figures here are population-average trial results, not predictions for any individual.